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Cell surface expression levels of GPRC5D, an orphan G protein–coupled receptor, are
significantly higher onmultiple myeloma (MM) cells, compared with normal plasma cells or
other immune cells, which renders it a promising target for immunotherapeutic strategies.
The novel GPRC5D-targeting T-cell redirecting bispecific antibody, talquetamab, effectively
kills GPRC5D1 MM cell lines in the presence of T cells from both healthy donors or heavily
pretreated MM patients. In addition, talquetamab has potent anti-MM activity in bone
marrow (BM) samples from 45 patients, including those with high-risk cytogenetic
aberrations. There was no difference in talquetamab-mediated killing of MM cells from
newly diagnosed, daratumumab-näıve relapsed/refractory (median of 3 prior therapies),
and daratumumab-refractory (median of 6 prior therapies) MM patients. Tumor cell
lysis was accompanied by T-cell activation and degranulation, as well as production of
pro-inflammatory cytokines. High levels of GPRC5D and high effector:target ratio were
associated with improved talquetamab-mediated lysis of MM cells, whereas an increased
proportion of T cells expressing PD-1 or HLA-DR, and elevated regulatory T-cell (Treg) counts
were associated with suboptimal killing. In cell line experiments, addition of Tregs to
effector cells decreased MM cell lysis. Direct contact with bone marrow stromal cells also
impaired the efficacy of talquetamab. Combination therapy with daratumumab or
pomalidomide enhanced talquetamab-mediated lysis of primary MM cells in an additive
fashion. In conclusion, we show that the GPRC5D-targeting T-cell redirecting bispecific
antibody talquetamab is a promising novel antimyeloma agent. These results provide the
preclinical rationale for ongoing studies with talquetamab in relapsed/refractory MM.
Introduction
The introduction of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs) and CD38-targeting
antibodies has substantially improved the outcome of multiple myeloma (MM) patients over the last two
decades.1 However, patients who become refractory to these therapies (triple-class refractory) have
a very poor outcome.2 New drugs, such as Selinexor and iberdomide, have shown activity in this
extensively pretreated group of patients.3,4 Several other promising novel agents are targeting B-cell
maturation antigen (BCMA), a member of the tumor necrosis factor (TNF) receptor superfamily that is
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highly and specifically expressed on plasma cells, including MM
cells.5-8 Particularly, BCMA-specific T-cell redirecting therapies,
such as chimeric antigen receptor (CAR) T cells, bispecific T-cell
engagers (BiTEs), and bispecific antibodies, have shown encour-
aging results with marked activity in preclinical MMmodels and early
phase clinical trials.7,9-12
Despite promising results with these BCMA-specific T-cell redi-
recting therapies, there is no plateau in the survival curves, and
eventually most patients will develop progressive disease. Mecha-
nisms underlying development of progressive disease include
heterogeneity in BCMA expression and (partial) loss of BCMA on
the MM cell surface levels during treatment.13-15 These observa-
tions, together with the increasing use of BCMA-targeting drugs,
underscore the need for additional targets for T-cell redirection
therapy in MM. Such proteins should be preferentially expressed on
the tumor cells, and not on critical normal tissues to prevent “on-
target/off-tumor” effects.
GPRC5D, an orphan G protein–coupled receptor of family C,
group 5, member D, is a promising novel target for MM immuno-
therapy. This 7-segment transmembrane protein was identified as
candidate target for anti-MM therapy by comparison of gene
expression profiles in unsorted bone marrow (BM) samples from
patients with hematological malignancies.16 GPRC5D is highly and
selectively expressed in MM cells,17-21 whereas in normal tissues, it
is only expressed in cells that produce hard keratin such as in hair
follicles.19,20,22 Although GPRC5D was discovered in the begin-
ning of this millennium,17 its endogenous ligand(s) and signaling
mechanism, and thereby its physiological function and its role in
cancer, remain unknown.
In this study, we aimed to further increase our understanding of
GPRC5D expression by measuring GPRC5D cell surface expres-
sion on MM cells from patients in different stages of the disease, as
well as on normal plasma cells and other immune cell subsets.
Moreover, we evaluated the preclinical activity of talquetamab,
a new humanized GPRC5DxCD3 bispecific antibody, in MM cell
lines and in fully autologous BM samples obtained from MM
patients. Importantly, the host immune system, including T-cell
function, can be affected by prior therapies, advanced disease, and
diverse components of the suppressive microenvironment, such as
BM stromal cells and regulatory T cells (Tregs). Therefore, we
specifically investigated the potential impact of previous therapy, as




Cell surface expression of GPRC5D was assessed in BM aspirates
obtained from newly diagnosed MM (NDMM) patients, primary
plasma cell leukemia patients (pPCL), daratumumab-naı̈ve relapsed/
refractory MM (RRMM) patients and daratumumab-refractory
(DARA-R) MM patients. Normal BM was obtained from age-
matched patients undergoing cardiothoracic surgery. In these
samples, we concurrently evaluated several other tumor char-
acteristics and immune cell composition. Ex vivo efficacy of
talquetamab was assessed when BM samples contained at least
2% MM cells and sufficient material was available. The samples
were analyzed within 24 hours after BM aspiration.
The study site ethics committee or institutional review board
approved the protocols, which were conducted according to the
principles of the Declaration of Helsinki, the International Confer-
ence on Harmonization, and the Guidelines for Good Clinical
Practice. All patients provided written informed consent.
Details and additional methods are presented in the supplemental
Data.
Results
Assessment of GPRC5D protein expressionmeasured
by flow cytometry
To gain deeper insight into GPRC5D cell surface expression (as
determined by median fluorescence intensity [MFI]), we performed
flow cytometry analysis on fresh BM samples from 74 MM patients
(see Table 1 for patient characteristics). There was a marked
heterogeneity in cell surface GPRC5D protein expression levels
on MM cells among patients, without a significant difference in the
extent of expression between NDMM (n5 27), daratumumab-naı̈ve
RRMM (n 5 22), and daratumumab-refractory RRMM (n 5 25)
patients (Figure 1A). Although numbers are small, the expression of
GPRC5D in pPCL samples (n 5 3) was comparable to NDMM
samples (data not shown). We also assessed GPRC5D expression
on normal plasma cells (PCs) in 11 BM samples obtained from age-
matched healthy donors (median age: 71 years old [range, 55-77]).
Higher GPRC5D cell surface levels were detected on MM cells
compared with normal PCs. GPRC5D levels on both normal and
clonal PCs were significantly higher compared with other immune
cells including B cells, T cells, natural killer (NK) cells, and NKT cells
(Figure 1B-C). By analyzing 11 additional BM samples, we show
that GPRC5D expression on MM cells as determined by MFI is
highly correlated with GPRC5D antibody-binding capacity (r 5
0.996, P , .0001; supplemental Figure 1). As expected, CD38
expression levels were higher on normal PCs when compared
with MM cells,23 whereas similar expression was observed for
BCMA (Figure 1D).
We also explored possible associations between GPRC5D cell
surface expression and several tumor and patient characteristics.
Tumor load, effector:target (E:T) ratio, age, sex, b2-microglobulin
levels, and lactate dehydrogenase levels did not affect GPRC5D
expression on MM cells. There was a weak positive correlation
between GPRC5D and estimated glomerular filtration rate (r 5
0.37; P5 .0018) as well as BCMA expression levels (r5 0.29; P5
.014), whereas there was no correlation with CD38 and PD-L1
expression (supplemental Figure 2).
GPRC5D gene expression
We next evaluated GPRC5D messenger RNA (mRNA) expression
in normal PCs from healthy controls and clonal PCs from patients
with monoclonal gammopathy of undetermined significance
(MGUS), smoldering MM (SMM), and newly diagnosed MM,
through the analysis of publicly available data sets. In agreement
with cell surface expression levels measured by flow cytometry,
gene expression levels of GPRC5D were significantly higher in MM
patients as compared with healthy controls. Intermediate GPRC5D
expression was observed in MGUS and SMM patients (Figure 1E).
To evaluate potential associations between GPRC5D mRNA
expression and clinical parameters, we analyzed mRNA data sets
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Table 1. Characteristics of MM patients and controls (samples used for assessment of GPRC5D expression)
HD (n 5 11) NDMM (n 5 27) RRMM (n 5 22) DARA-R MM (n 5 25)
Age, median (range), y 71 (55-77) 66 (49-86) 67 (54-77) 66 (50-80)
Male, n (%) 9 (82) 16 (59) 13 (59) 15 (60)
LDH, U/L
Median (range) 207 (111-490) 212 (78-1505) 195 (110-544)
Unknown, n (%) 10 (37) 0 4 (16)
Elevated, n (%) 6 (35) 6 (27) 6 (29)
eGFR, mL/min/1.73 m2
Median (range) 80 (23-90) 78 (42-90) 78 (36-90)
Unknown, n (%) 6 (22) 0 0
,60, n (%) 2 (10) 4 (18) 6 (24)
,30, n (%) 1 (5) 0 0
b2-microglobulin, median (range), mg/L 3.2 (1.8-11.0) 3.7 (2.0-12.0) 4.4 (1.7-9.0)
Unknown, n (%) 4 (15) 4 (18) 13 (52)
M protein, n (%)
IgG 9 (36) 17 (77) 16 (64)
IgA 5 (20) 3 (14) 4 (16)
FLC only 10 (40) 2 (9) 3 (12)
Nonsecretor 0 0 1 (4)
Other 1 (4): IgM 0 1 (4): IgD
Unknown 2 (7) 0 0





High-risk cytogenetics,* n (%) 3 (12) 7 (33) 5 (36)
Unknown 1 (4) 1 (5) 11 (44)
del(17p) 1 (4) 5 (24) 4 (29)
t(4;14) 1 (4) 1 (5) 1 (7)
t(14;16) 1 (4) 1 (5) 0
Prior lines, median (range) 0 3 (1-8) 6 (1-16)
Prior autologous SCT, n (%) NA 15 (68) 15 (60)
Single 12 (55) 11 (44)
Double 3 (14) 4 (16)
Prior allogeneic SCT, n (%) NA 0 1 (4)
Lenalidomide, n (%) NA
Exposed 20 (91) 24 (96)
Refractory† 20 (91) 24 (96)
Pomalidomide, n (%) NA
Exposed 9 (41) 13 (52)
Refractory 8 (36) 12 (48)
*Based on the presence of del(17p), t(4;14), and/or t(14;16).
†Refractory disease was defined as progressive disease during therapy, no response (less than partial response), or progressive disease within 60 days of stopping treatment, according to the
International Uniform Response Criteria for Multiple Myeloma.
‡Lenalidomide and/or pomalidomide.
§Bortezomib, carfilzomib, and/or ixazomib.
||At least 1 IMiD plus 1 PI and CD38-targeting antibody.
eGFR; estimated glomerular filtration rate; FLC, free light chains; HD, healthy donor; Ig, immunoglobulin; ISS, International Staging System; LDH, lactate dehydrogenase; NA, not applicable;
SCT, stem cell transplantation.
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derived from a total of 1421 MM patients who participated in 5
different prospective clinical studies. GPRC5D gene expression
levels were highly variable and independent of age and International
Staging System score (data not shown). Significantly higher
GPRC5D levels were observed in patients with t(4;14) and gain
1q, and significantly lower levels in patients with t(11;14) (Figure 1F).
Although not significant, a similar trend for GPRC5D cell surface
protein expression was observed in in our smaller cohort of 60
patients with available flow cytometry and cytogenetic data (supple-
mental Figure 3).We found no association between other cytogenetic
abnormalities and GPRC5D expression. Univariate Cox regression
analysis showed thatGPRC5D expression levels were not associated
with progression-free survival or overall survival (Figure 1G).
Talquetamab is effective in GPRD5D1 MM cell lines
The selective expression of GPRC5D on MM cells renders
GPRC5D a potential immunotherapeutic target for the treatment
of MM. We therefore analyzed the activity of the novel GPRC5DxCD3
bispecific antibody, talquetamab, in 4 MM cell lines (U266, RPMI-
8226, MM.1S, and UM9) with different expression levels of
GPRC5D, and in a GPRC5D-negative lymphoma cell line (Raji), by
using a bioluminescence imaging (BLI)-based cytotoxicity assay.
These cell lines were incubated with serial concentrations of
talquetamab for 48 hours in the presence of healthy donor–derived
peripheral blood mononuclear cells (PB-MNCs). As expected,
talquetamab did not affect the viability of GPRC5D2 U266 or Raji
cells, but there was dose-dependent lysis of the 3 GPRC5D1 cell
lines, with near-complete elimination of MM cells starting at 0.16
mg/mL talquetamab (Figure 2A-B). The most sensitive cell lines,
UM9 and MM.1S, had highest GPRC5D expression. Additional
experiments showed that cytolysis increased in an E:T ratio and
time-dependent manner (Figure 2C; supplemental Figure 4).
Consistent with a T cell–dependent mode of action, talquetamab
treatment led to a dose-dependent activation and degranulation of
Table 1. (continued)
HD (n 5 11) NDMM (n 5 27) RRMM (n 5 22) DARA-R MM (n 5 25)
Bortezomib, n (%) NA
Exposed 20 (91) 23 (92)
Refractory 5 (23) 13 (52)
Carfilzomib, n (%) NA
Exposed 9 (41) 10 (40)
Refractory 6 (27) 6 (24)
Ixazomib, n (%) NA
Exposed 1 (5) 3 (12)
Refractory 1 (5) 2 (8)
Daratumumab, n (%) NA
Exposed 0 25 (100)
Refractory 0 25 (100)
BCMAxCD3 antibody, n (%) NA
Exposed 0 2 (8)
Refractory 0 2 (8)
IMiD,‡ n (%) NA
Exposed 20 (91) 24 (96)
Refractory 20 (91) 24 (96)
PI,§ n (%) NA
Exposed 22 (100) 24 (96)
Refractory 11 (50) 18 (72)
IMiD and PI, n (%) NA
Exposed 20 (91) 24 (96)
Refractory 11 (50) 18 (72)
Triple class,|| n (%) NA
Exposed 0 24 (96)
Refractory 0 18 (72)
*Based on the presence of del(17p), t(4;14), and/or t(14;16).
†Refractory disease was defined as progressive disease during therapy, no response (less than partial response), or progressive disease within 60 days of stopping treatment, according
to the International Uniform Response Criteria for Multiple Myeloma.
‡Lenalidomide and/or pomalidomide.
§Bortezomib, carfilzomib, and/or ixazomib.
||At least 1 IMiD plus 1 PI and CD38-targeting antibody.
eGFR; estimated glomerular filtration rate; FLC, free light chains; HD, healthy donor; Ig, immunoglobulin; ISS, International Staging System; LDH, lactate dehydrogenase; NA, not
applicable; SCT, stem cell transplantation.
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Figure 1. GPRC5D protein and RNA expression levels in normal and clonal plasma cells. (A) Cell surface expression of GPRC5D, as determined by MFI, on plasma
cells was assessed by flow cytometry in BM samples obtained from 27 NDMM, 22 daratumumab-naı̈ve RRMM, and 25 daratumumab-refractory MM patients and in normal BM
from 11 age-matched healthy donors. Groups were compared using Mann-Whitney U test. (B) GPRC5D cell surface protein expression on MM cells was compared with the
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both CD41 and CD81 T cells, as evidenced by the increased cell
surface expression of CD25 and CD107a, respectively (Figure 2D).
T-cell activation was accompanied by increased secretion of
interferon (IFN)-g; TNF-a; interleukin-2 (IL-2), IL-4, IL-6, IL-10, IL-
17A; and granzyme B, as shown in Figure 2E for RPMI-8226.
Similar data were obtained with MM.1S cells (data not shown).
Similar talquetamab-mediated MM cell lysis using
T cells obtained from MM patients or healthy controls
It is currently unknown whether T cells from MM patients have
similar cytotoxic activity compared with healthy donor-derived
T cells. We therefore evaluated whether talquetamab is also
capable of killing MM cells in the presence of PB-MNCs obtained
from heavily pretreated daratumumab-naı̈ve RRMM patients (me-
dian of 3 prior lines of therapy [range, 2-7]; 66% IMiD and PI
refractory). Importantly, there was no significant impairment in
talquetamab-mediated killing when using patient-derived PB-MNCs
when compared with healthy donor PB-MNCs (Figure 2F).
Impact of stromal cells on the efficacy of talquetamab
BM stromal cells (BMSCs) contribute to resistance of MM cells
against several therapies, including daratumumab24 and MM-
reactive T cells.25,26 We therefore evaluated the impact of BMSCs
obtained from MM patients on the efficacy of talquetamab. In 2
of the 3 GPRC5D-positive MM cell lines, BMSCs significantly
impaired talquetamab-mediated lysis, whereas the activity of
talquetamab against UM9 cells was not affected (Figure 3A).
Next, we examined whether BMSCs protect MM cells against
talquetamab-mediated lysis through cell-derived soluble factors or
direct cell–cell contact by performing transwell experiments.
BMSCs significantly inhibited talquetamab-mediated MM cell lysis
in cocultures where they were in direct contact with MM cells.
However, when BMSCs were separated from MM cells by
microporous membrane inserts (indirect contact), the inhibitory
capacity was substantially diminished (Figure 3B). This indicates
that cell–cell contact is required to reduce talquetamab-
mediated MM cell lysis, whereas BMSC-derived soluble factors
alone do not impair the activity of talquetamab.
The protection conferred by BMSCs against talquetamab-mediated
lysis may be due to acquired resistance of MM cells (eg, altered
target expression following adhesive interactions) and/or T-cell
suppression. Additional experiments showed that contact with
BMSCs resulted in reduced expression of GPRC5D on RPMI-8226
and MM.1S cells, but not on UM9 cells, correlating with BMSC-
mediated talquetamab resistance of RPMI-8226 and MM.1S, but
not of UM9 (Figure 3C). However, talquetamab-mediated lysis was
inhibited by BMSCs without a reduction in T-cell activation and
degranulation, indicating the induction of cell intrinsic resistance
mechanisms against the cytotoxic machinery of T cells by BMSCs
(supplemental Figure 5). Similar results were obtained when CD41
and CD81 T cells were analyzed separately.
Talquetamab induces T-cell activation and T-cell
degranulation and kills primary MM cells obtained
from NDMM and RRMM patients
To evaluate the efficacy of talquetamab against primary MM cells,
we treated BM mononuclear cells (BM-MNCs; containing tumor
cells, as well as autologous effector cells and immune suppressor
cells) from 45 patients with talquetamab for 48 hours, after which
survival of MM cells was determined by enumeration of viable
CD1381 cells by flow cytometry (see Table 2 for patient
characteristics). Talquetamab effectively induced MM cell lysis
(mean lysis with 4.0 mg/mL talquetamab [dose whereby a plateau
in MM cell lysis was observed]: 61%; range: 25% to 97%;
Figure 4A; supplemental Figure 6A-B), whereas there was a modest
increase in NK cells and a small decrease in T-cell counts
(Figure 4B). The control antibodies (immunoglobulin G1 isotype
control, CD3xnull, and GPRC5Dxnull) showed significantly lower
anti-MM activity in these patient samples, confirming the re-
quirement for cross-linking of target cells and T cells, and ruling
out a direct effect of GPRC5D targeting. Importantly, there was no
difference in talquetamab-mediated killing of MM cells from NDMM
(n 5 13; mean lysis at 4.0 mg/mL: 59%), daratumumab-naı̈ve
RRMM (n 5 17; median of 3 prior lines of therapy; 88%
lenalidomide-refractory and 24% bortezomib-refractory; mean lysis:
63%), or daratumumab-refractory MM patients (n 5 15; median of
6 prior lines of therapy; 100% lenalidomide-refractory and
60% bortezomib-refractory; mean lysis: 64%) (Figure 4C). The
daratumumab-refractory status of the latter group of patients was
confirmed by their low ex vivo daratumumab sensitivity, when
compared with daratumumab-naı̈ve patients (supplemental
Figure 6C). Furthermore, talquetamab was also effective in 1 of 2
samples obtained from patients who progressed during treatment
with a BCMA-targeting bispecific antibody. The nonresponding
patient had low GPRC5D expression on MM cells (supplemental
Figure 7A). We also observed high activity in 2 samples obtained
from pPCL patients (supplemental Figure 7B).
Talquetamab-mediated lysis of MM cells was accompanied by
a significant increase in the proportion of activated CD41 and
CD81 T cells, as evidenced by CD25 induction on the cell surface
(Figure 4D). Talquetamab treatment also resulted in a significant
degranulation of CD41 and CD81 T cells, as determined by
induction of cell surface CD107a expression. At higher concen-
trations, talquetamab-mediated T-cell activation was significantly
higher in NDMM compared with RRMM patient samples, whereas
there was no difference in extent of T-cell degranulation among
the 3 patient groups (Figure 4E). As expected, no activation or
degranulation of NK cells was observed (Figure 4D). We also
Figure 1. (continued) expression on BM-localized immune cells in the same patient’s samples by Wilcoxon matched-pairs test. (C) The same analysis was performed in BM
samples obtained from healthy donors (n 5 11). (D) Cell surface expression of BCMA and CD38 on plasma cells in BM samples from the same patients and healthy donors. (E)
Gene expression profiling was performed on purified CD1381 plasma cells, publicly available datasets were used. mRNA expression of GPRC5D was compared between normal
plasma cells obtained from healthy donors and clonal plasma cells from MGUS, SMM and NDMM patients. GPRC5D mRNA expression is plotted as Log2 transformed, MAS5
normalized values. (F) In datasets from 5 large trials (HOVON65, TT2, TT3, MRC IX, and APEX, n 5 1421), GPRC5D mRNA expression in MM cells was compared between
patients with or without specific cytogenetic abnormalities (gain(1q), del(13q), del(17p), and IGH translocations [t(4;14), t(11;14), and t(MAF)]). Groups were compared using
Wilcoxon rank-sum test. (A-F) Each dot represents an individual sample, with box and whiskers, representing median, 25th-75th percentile, and range. (G) Univariate Cox regression
analysis was performed to evaluate the effect of GPRC5D expression on progression-free survival and overall survival. *P , .05; ***P , .001; ****P , .0001. ns, not significant.

















































































































































































































































































































































































































































































































































Figure 2. Talquetamab-mediated lysis of cell lines. (A) GPRC5D protein expression on cell lines was assessed by flow cytometry. Representative overlay histograms
depict GPRC5D cell surface expression (red histogram) on 4 luciferase-transduced (LUC1) MM cell lines (U266, RPMI-8226, MM.1S, UM9) and the LUC1 Burkitt lymphoma
cell line Raji, compared with isotype control (gray histogram). GPRC5D MFI is provided. (B) These cell lines were incubated with solvent control, serial dilutions of talquetamab
(0.00128-4.0 mg/mL), or control antibodies, together with PB-MNCs obtained from healthy donors as effector cells, at an E:T ratio of 10:1 for 48 hours. Tumor cell lysis was
assessed by using a BLI-based cytotoxicity assay. Data represent mean MM lysis 6 standard error of mean (SEM) of 3 to 5 independent experiments, performed in duplicate.
Half maximal effective concentration (EC50) values are provided. (C) LUC
1 RPMI-8226 cells were incubated for 48 hours with solvent control or serial dilutions of talquetamab
(0.00128-4.0 mg/mL), and PB-MNCs obtained from healthy donors as effector cells at different E:T ratios (10:1, 3:1, 1:1, 1:3, and 1:10). MM cell lysis was determined by
using a BLI-based cytotoxicity assay. Data represent mean MM lysis 6 SEM of 3 independent experiments, performed in duplicate. (D) Talquetamab-mediated activation and
degranulation of healthy CD41 and CD81 T cells were assessed by flow cytometric analysis of CD25 and CD107a cell-surface expression, respectively (n 5 3). Representa-
tive flow cytometry histogram overlays depict cell surface expression of CD25 and CD107a on CD41 (green) and CD81 (purple) T cells treated with talquetamab (4.0 mg/mL)
or solvent control (gray). (E) Pro-inflammatory cytokines and granzyme B were measured in cell-culture supernatants from RPMI-8226 cells treated with talquetamab
(0.032-4.0 mg/mL) in the presence of PB-MNCs obtained from healthy donors for 48 hours, by using a flow cytometry-based assay and an enzyme-linked immunosorbent
assay, respectively. Bars represent mean 6 SEM of 3 independent experiments, performed in triplicate. (F) RPMI-8226 cells were incubated with solvent control or serial
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evaluated cytokine and granzyme B levels in supernatants from
6 RRMM patients. Talquetamab treatment resulted in a dose-
dependent increase in levels of granzyme B and cytokines (in
particular IL-6, IL-8, TNF-a, and IFN-g) (Figure 4F).
Effect of talquetamab on normal PCs
Because normal PCs expressed significantly lower GPRC5D, but
higher CD38 levels, compared with malignant PCs, we also
assessed to what extent talquetamab and daratumumab eliminate
normal PCs. To this end, BM-MNCs obtained from age-matched
healthy controls were incubated with these antibodies for 48 hours.
Talquetamab-mediated lysis of normal PCs was significantly lower
compared with daratumumab (supplemental Figure 8).
Impact of tumor and host characteristics on
talquetamab-mediated MM cell lysis
Because extent of prior therapy does not explain the variability in
sensitivity, we examined whether baseline tumor characteristics
have an impact on the susceptibility of MM cells toward
talquetamab. To this end, patients were divided into 2 groups
according to whether the value of a continuous variable was above
or below the median value of all tested samples (see supplemental
Figure 9A for the distribution of each variable), and dose-response
curves were compared between both groups (Figure 5A). Across
BM samples, the efficacy of talquetamab was superior in patients
with higher than median cell surface expression levels of GPRC5D,
when compared with patients with lower expression (P , .0001).
Figure 2. (continued) dilutions of talquetamab (0.00128-4.0 mg/mL), and PB-MNCs derived from 4 healthy donors or from 9 RRMM patients (median of 3 prior lines of
therapy, 66% refractory for both IMiD and PI; PB was obtained at the time of progression during last line of therapy) at an E:T ratio of 10:1. After a 48 hour-incubation, lysis of
RPMI-8826 cells was determined by BLI. Data represent mean MM lysis 6 SEM; each individual experiment was performed in duplicate. Differences in talquetamab-mediated





















































































































































Figure 3. Talquetamab-mediated lysis is hampered by the presence of BMSCs in 2 of 3 cell lines. (A) Luciferase-transduced cell lines RPMI-8226, MM.1S, and UM9
were incubated with solvent control, serial dilutions of talquetamab (0.00128-4.0 mg/mL), or control antibodies, and with PB-MNCs obtained from healthy donors at an E:T
ratio of 10:1, in the absence or presence of BMSCs (ratio of BMSCs to MM cells was 2:1). After a 48-hour incubation, MM cell lysis was assessed using a BLI-based
cytotoxicity assay. Data represent mean MM lysis 6 SEM of 3 to 4 independent experiments performed in duplicate. Differences in talquetamab-mediated tumor cell lysis in the
presence or absence of BMSCs were calculated using nonlinear regression analysis; P values are provided. (B) The indirect or direct impact of BMSCs on talquetamab-
mediated lysis was evaluated by performing transwell experiments in which MM cells (RPMI-8226 or MM.1S cells) and PB-MNCs obtained from healthy donors were placed in
the lower chambers, and no cells (medium alone) or BMSCs (indirect contact) were placed in the upper chambers. To study direct cell contact, all cell types were combined in
the lower chambers. Cells were incubated with serial dilutions of talquetamab (0.032-4.0 mg/mL) or control antibodies for 48 hours. Lysis of MM cells was assessed using
a BLI assay. Data represent mean lysis 6 SEM of 3 independent experiments, performed in duplicate or triplicate. The impact of direct or indirect contact with BMSCs was
calculated using nonlinear regression analysis and 2-way analysis of variance test; P values are provided. (C) GPR5D expression on MM cells was assessed by flow cytometry
after a 48-hour incubation in the presence or absence of BMSCs. Paired Student t test was used to evaluate significance between both groups.
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Table 2. Characteristics of MM patients (samples used in cytotoxicity assays)
NDMM (n 5 13) RRMM (n 5 17) DARA-R MM (n 5 15)
Age, median (range), y 63 (49-86) 68 (54-77) 68 (57-80)
Male, n (%) 8 (62) 12 (71) 11 (73)
LDH, U/L
Median (range) 223 (156-490) 217 (78-1505) 209 (110-544)
Unknown, n (%) 4 (31) 0 1 (7)
Elevated, n (%) 4 (44) 6 (35) 4 (27)
eGFR, mL/min/1.73 m2
Median (range) 85 (23-90) 69 (42-90) 78 (43-90)
Unknown, n (%) 3 (23) 0 0
,60, n (%) 1 (10) 1 (6) 4 (27)
,30, n (%) 1 (10) 0 0
b2-microglobulin, median (range), mg/L 3.3 (1.8-10.0) 4.1 (2.0-6.2) 4.0 (1.7-7.9)
Unknown, n (%) 1 (8) 2 (12) 9 (60)
M protein, n (%)
IgG 7 (58) 13 (76) 9 (60)
IgA 2 (17) 3 (18) 3 (20)
FLC only 3 (25) 1 (6) 2 (13)
Nonsecretor 0 0 1 (7)
Unknown 1 (8) 0 0





High-risk cytogenetics,* n (%) 1 (8) 6 (38) 3 (33)
Unknown 0 1 (6) 6 (40)
del (17p) 0 4 (25) 3 (33)
t (4;14) 0 2 (13) 0
t (14;16) 1 (8) 0 0
Prior lines, median (range) 0 3 (1-8) 6 (3-16)
Prior autologous SCT, n (%) NA 11 (65) 9 (60)
Single 8 (47) 5 (33)
Double 3 (18) 4 (27)
Lenalidomide, n (%) NA
Exposed 15 (88) 15 (100)
Refractory† 15 (88) 15 (100)
Pomalidomide, n (%) NA
Exposed 7 (41) 7 (47)
Refractory 6 (35) 7 (47)
Bortezomib, n (%) NA
Exposed 16 (94) 14 (93)
Refractory 4 (24) 9 (60)
*Based on the presence of del(17p), t(4;14), and/or t(14;16).
†Refractory disease was defined as progressive disease during therapy, no response (less than partial response), or progressive disease within 60 days of stopping treatment, according to the
International Uniform Response Criteria for Multiple Myeloma.
‡Lenalidomide and/or pomalidomide.
§Bortezomib, carfilzomib, and/or ixazomib.
||At least 1 IMiD plus 1 PI and CD38-targeting antibody.
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T-cell activation and degranulation were both significantly higher in
samples from patients with high GPRC5D expression, compared
with those with low expression, reflecting the higher efficacy of
talquetamab against MM cells with high GPRC5D expression. As
expected, talquetamab activity was not associated with cell surface
expression levels of BCMA and CD38. Importantly, the presence of
high-risk cytogenetic abnormalities (del(17p), t(4;14), and/or t(14;
16)) did not impair talquetamab activity. Similar results were obtained
when chromosome 1 abnormalities were included in the definition of
high-risk disease. Because aging is accompanied by a decline in
immune function, we also assessed the effect of age on talquetamab-
mediated tumor cell lysis. In samples derived from older patients (age
.67 years), talquetamab activity was impaired, which was accom-
panied by inferior T-cell activation and degranulation.
Impact of immune characteristics on
talquetamab-mediated MM cell lysis
Next, we assessed whether the variability in response to
talquetamab could be explained by naturally occurring differences
in the composition of the immune system in these BM samples.
Because the patients’ samples contained variable amounts of
T cells and MM cells, we first analyzed the impact of T-cell frequency
and E:T ratio in the BM-MNCs on talquetamab-mediated MM cell
lysis. The dose-response curves show that talquetamab is
significantly less effective in patients with a low T-cell frequency
or low E:T ratio (# median), when compared with patients with
a high T-cell frequency or high E:T ratio (Figure 5B). Furthermore,
the proportions of activated and degranulated T-cells induced in
response to talquetamab treatment were significantly lower in
patients with high T-cell frequency or E:T ratio, when compared with
a T-cell frequency or E:T ratio below the median. Similar
observations were made when CD41 T cells and CD81 T cells
were analyzed separately (data not shown). The CD4:CD8 ratio had
no impact on talquetamab activity (data not shown). In contrast,
a high frequency of Tregs (. median) impaired talquetamab-
mediated lysis of MM cells, and this was accompanied by inferior
T-cell activation and trend toward diminished T-cell degranulation
(Figure 5B; supplemental Figure 9A-B for distribution of variables
and Treg gating strategy). A high frequency of PD-11 T cells (.
median) was also associated with reduced activity of talquetamab,
but not with a significant difference in T-cell activation or
degranulation. A lower frequency of activated T cells (defined by
the expression of HLA-DR) at baseline resulted in more effective
Table 2. (continued)
NDMM (n 5 13) RRMM (n 5 17) DARA-R MM (n 5 15)
Carfilzomib, n (%) NA
Exposed 5 (29) 7 (46)
Refractory 2 (12) 4 (27)
Ixazomib, n (%) NA
Exposed 1 (6) 0
Refractory 1 (6) 0
Daratumumab, n (%) NA
Exposed 0 15 (100)
Refractory 0 15 (100)
BCMAxCD3 antibody, n (%) NA
Exposed 0 2 (13)
Refractory 0 2 (13)
IMiD,‡ n (%) NA
Exposed 15 (88) 15 (100)
Refractory 15 (88) 15 (100)
PI,§ n (%) NA
Exposed 17 (100) 15 (100)
Refractory 6 (35) 11 (73)
IMiD and PI, n (%) NA
Exposed 15 (88) 15 (100)
Refractory 6 (35) 11 (73)
Triple class,|| n (%) NA
Exposed 0 15 (100)
Refractory 0 11 (73)
*Based on the presence of del(17p), t(4;14), and/or t(14;16).
†Refractory disease was defined as progressive disease during therapy, no response (less than partial response), or progressive disease within 60 days of stopping treatment, according
to the International Uniform Response Criteria for Multiple Myeloma.
‡Lenalidomide and/or pomalidomide.
§Bortezomib, carfilzomib, and/or ixazomib.
||At least 1 IMiD plus 1 PI and CD38-targeting antibody.

















































































































































































































































































































































































































































































































































































































































































































Figure 4. Talquetamab-mediated lysis of primary MM cells. BM-MNCs obtained from 13 NDMM, 17 daratumumab-naı̈ve RRMM, and 15 daratumumab-refractory RRMM
patients were incubated with solvent control, serial dilutions of talquetamab (0.00128-4.0 mg/mL), and control antibodies (4.0 mg/mL) for 48 hours, after which surviving
CD1381 MM cells (A), as well as T and NK cells (B), were enumerated using flow cytometric analysis. Lysis (y-axis) of MM cells (red), T cells (orange) and NK cells (gray) is
depicted in the graphs. Negative lysis values indicate that cell numbers are higher when compared with solvent control. (C) Talquetamab-mediated tumor cell lysis in samples
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talquetamab-mediated lysis, accompanied by higher percentages of
activated T cells. The frequencies of T-cell memory subsets (naive,
central memory, effector memory, or terminally differentiated
effector memory) were not associated with response to talqueta-
mab or differences in T-cell activation or degranulation (Figure 5B
shows data for naive T cells).
Tregs impair lysis of MM cells
Because Tregs have a negative impact on talquetamab-mediated
killing of primary MM cells, we performed additional experiments to
analyze the killing capacity of Tregs in response to talquetamab, and
whether Tregs impair the cytotoxic activity of effector T cells. To this
end, we isolated Tregs according to phenotypic CD41CD251
CD1272/low expression, and conventional CD41CD252 T cells as
control from buffy coats obtained from healthy donors (Figure 6A).
To confirm that these CD41CD251CD1272/low cells exhibit the
functional characteristics of Tregs, we first performed coculture
experiments with autologous CD41CD252 T cells to examine the
suppressive capacity of the Tregs. Stimulation of CD41CD252
T cells with anti-CD3/CD28-coated beads resulted in a strong
proliferative response, which was inhibited in the presence of Tregs
(Figure 6B). Next, RPMI-8226 cells were treated with talquetamab
in the presence of purified Tregs and/or CD41CD252 T cells as
effector cells. After 48 hours of coculture, we demonstrate the
ability of Tregs to directly eliminate MM cells in the presence of
talquetamab. However, MM cell lysis mediated by redirected Tregs
was significantly lower than what was observed with redirected
CD41CD252 T cells. Moreover, the addition of Tregs to CD41
CD252 T cells significantly impaired lysis of RPMI-8226 cells,
compared with CD41CD252 T cells alone (Figure 6C). Accord-
ingly, talquetamab-induced production of pro-inflammatory cyto-
kines (IFN-g, TNF-a, IL-2) was lower in the presence of Tregs alone,
and in the combination of Tregs plus CD41CD252 T cells,
compared with CD41CD252 T cells alone (Figure 6D). Although
not significant, a similar trend was observed for granzyme B release
(Figure 6D).
Combination therapy with daratumumab
and pomalidomide
Because failure of immunotherapy may be caused by antigen loss,
the simultaneous targeting of multiple antigens can be a new
therapeutic approach to improve clinical outcome. To investigate
whether the direct combination of talquetamab with the CD38-
targeting antibody daratumumab enhanced tumor cell lysis, BM-
MNCs from 25 MM patients were incubated with serial dilutions of
talquetamab and with daratumumab (0.1 mg/mL) for 48 hours.
Cotreatment with daratumumab enhanced talquetamab-mediated
lysis of primary MM cells (n 5 8 NDMM, n 5 11 RRMM, and n 5 6
DARA-R MM) in an additive fashion (Figure 7A; supplemental
Figure 10A). Because activated T cells have increased CD38
expression, we also evaluated the impact of daratumumab on the
proportion of CD381 T cells and on T-cell numbers. Talquetamab
treatment resulted in an increased frequency of CD381 T cells,
which was almost completely abrogated by daratumumab
(Figure 7B). Daratumumab also reduced the proportion of activated
and degranulated T cells, but had no effect on T-cell numbers
(Figure 7C). In additional MM cell line experiments, we observed
that daratumumab did enhance talquetamab-mediated MM cell lysis
in the presence of PB-MNCs, but not in the presence of purified
T cells (.99% purity). This indicates that next to T cells, other cells
such as Fc-receptor-bearing NK cells, are essential to obtain
additivity between both immunotherapeutic agents in these short-
term experiments (supplemental Figure 11).
Because of the immunomodulatory effects of pomalidomide, we
also evaluated combination treatment with talquetamab and
pomalidomide (2 mM) in 13 BM samples. We selected pomalido-
mide for these experiments because it has superior immune
stimulatory activity, when compared with other approved IMiDs.27
Direct co-incubation with pomalidomide moderately enhanced
talquetamab-mediated lysis of MM cells in an additive fashion,
which was associated with increased T-cell numbers at suboptimal
talquetamab concentrations, superior T-cell activation, and in-
creased granzyme B secretion (Figure 7D-F; supplemental
Figure 10B). We next cocultured pomalidomide-pretreated PB-
MNCs and RPMI-8226 target cells with talquetamab, with or
without pomalidomide for 4 days, and observed improved MM cell
lysis with both drugs through additive effects (supplemental
Figure 12A). With combined talquetamab-pomalidomide treatment,
there was no significant change in the proportions of T-cell
differentiation subsets, compared with what was observed with
talquetamab alone. However, there was a trend toward a lower Treg
frequency with combination treatment (supplemental Figure 12B).
Discussion
Our gene expression profiling and flow cytometry data show
that MM cells express significantly higher levels of GPRC5D mRNA
and protein when compared with normal plasma cells. In addition,
our data complement the findings of Kodama et al20 that GPRC5D
protein expression in the BM is restricted to plasma cells. Outside
the BM, theGPRC5D gene is only expressed in differentiating cells
that produce hard keratin.19,20,22 Importantly, heavily pretreated
patients continue to express GPRC5D, indicating that IMiDs,
PIs, and CD38-targeting antibodies do not markedly affect the
expression of GPRC5D on MM cells.
Figure 4. (continued) obtained from NDMM (lime green), daratumumab-naı̈ve RRMM (light blue), and daratumumab-refractory RRMM (magenta) patients was compared
using nonlinear regression analysis. EC50 values are provided for each patient category. (D) Talquetamab-mediated activation and degranulation of CD4
1 T cells, CD81 T cells,
and NK cells were assessed after a 48-hour culture in all 45 patient samples by flow cytometric analysis of CD25 and CD107a cell surface expression, respectively. Data
represent mean 6 SEM; experiments performed in duplicate. Representative flow cytometry histogram overlays depict cell surface expression of CD25 (green) and CD107a
(purple) on CD41 and CD81 T cells treated with talquetamab (4.0 mg/mL) for 48 hours, compared with solvent control (gray). (E) T-cell activation and T-cell degranulation
were also assessed per patient category (NDMM [lime green], daratumumab-naı̈ve RRMM [light blue], and daratumumab-refractory RRMM [magenta]), and compared using
nonlinear regression analysis. (F) Granzyme B and cytokines were measured in the cell-culture supernatants of BM-MNCs treated with solvent control or talquetamab for 48
hours. BM-MNCs were obtained from 5 daratumumab-naı̈ve RRMM and 1 daratumumab-refractory RRMM patient. Data are depicted as different symbols, representing the
mean of 4 measurements per patient, with box and whiskers, representing median values, 25th-75th percentile, and range. Data were normalized to solvent control. GZMB,
granzyme B.















































































































































































































































































































Figure 5. Impact of tumor, patient and immune characteristics on talquetamab-mediated lysis, T-cell activation, and degranulation. The impact of tumor and
patient characteristics (A) and immune characteristics (B) on talquetamab-mediated activity was assessed by constructing dose-response curves for talquetamab-mediated MM
cell lysis (panels I), talquetamab-mediated T-cell activation based on frequency of CD251 T cells (panels II), and talquetamab-mediated T-cell degranulation based on frequency
of CD107a1 T cells (panels III), according to median expression levels (GPRC5D, BCMA), median percentage of immune cell subsets (T cells, Tregs, PD-11 T cells, HLA-DR1
T cells, naı̈ve T cells), median E:T ratio, median age, as well as presence of high-risk cytogenetic aberrations. Patient samples were obtained from 13 NDMM, 17 daratumumab-
naı̈ve RRMM, and 15 daratumumab-refractory RRMM patients. Data represent mean 6 SEM, samples with a value # median value of all tested samples are depicted in blue
and . median value in red. Groups were compared by nonlinear regression analysis. P values are provided.
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The high expression in MM cells, across all stages of the disease,
with no or only limited expression in normal tissues, renders
GPRC5D a promising target for anti-MM immunotherapy. Indeed,
our data show that talquetamab redirects T cells to MM cells by
cross-linking the activating receptor CD3 on T cells and GPRC5D
on the cell surface of the tumor cells. Talquetamab-mediated killing
of MM cells occurs via the coupling of both CD41 and CD81 T cells
with GPRC5D1 MM cells, which is followed by T-cell activation,
pro-inflammatory cytokine secretion, and T-cell degranulation with
release of cytotoxic molecules such as granzyme B.
Data on the efficacy of GPRC5D-bispecific antibodies against
primary MM cells in patient samples are very limited. Activity of
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in 1 study,20 whereas another report assessed activity in MM cell
lines and only 4 thawed BM samples supplemented with exogenous
T cells from healthy donors.28 We therefore evaluated talquetamab-
mediated killing of MM cells in a large number of fresh patient
samples (n 5 45). To this end, we used mononuclear cells isolated
from fresh BM aspirates obtained from patients, which not only
contain MM cells but also autologous effector cells, stromal cells,
and immune suppressor cells. This extensive analysis of ex vivo
sensitivity to talquetamab, showed that the GPRC5D bispecific
antibody effectively induced MM cell death without a difference in
activity between samples obtained from newly diagnosed MM or
heavily pretreated, double- or triple-class, refractory MM patients. In
accordance with these results, we demonstrate in a MM cell line
model that T cells from heavily pretreated patients had similar
cytotoxic activity after stimulation with talquetamab, compared with
T cells from healthy donors. These observations are remarkable
because RRMM patients have a more immunosuppressive
microenvironment.29,30 Furthermore, cumulative exposure to immu-
nosuppressive therapies, such as dexamethasone and proteasome
inhibitors, also contributes to impaired T-cell function during
disease evolution.31,32 In addition, our data indicate that mecha-
nisms of resistance to prior therapies such as IMiDs, PIs, and
daratumumab do not result in reduced susceptibility to talquetamab-
mediated lysis. Importantly, talquetamab triggers MM cell death
regardless of presence of high-risk cytogenetic abnormalities. Even in
samples obtained from patients with pPCL, which is considered the
most aggressive plasma cell disorder, talquetamab exhibited sub-
stantial ex vivo activity.9,33 Furthermore, we show high antitumor
activity of talquetamab against MM cells from a patient, who
progressed during BCMA bispecific antibody treatment. More data
are needed on the value of GPRC5D-targeting T-cell redirecting
therapies after failure of BCMA-targeted therapy.
Talquetamab-mediated tumor cell lysis was variable across patient
samples, with a significant positive association between GPRC5D
expression on MM cells and the capability of talquetamab to kill MM
cells. In addition, superior T-cell activation and degranulation was
observed in samples with GPRC5D expression levels above the
median. Importantly, the variability in response could not be solely
explained by differential expression of GPRC5D. Indeed, we show
that variability in the BM immune microenvironment also contributes
to the differential ex vivo therapeutic efficacy of talquetamab. First, in
experiments with MM cell lines and samples from MM patients, we
demonstrate that higher E:T ratios at baseline are associated with
improved elimination of MM cells by talquetamab. In samples with
high E:T ratio, the relative abundance of T cells also resulted in
reduced proportion of activated and degranulated T cells following
talquetamab treatment. Second, a high proportion of T cells
expressing PD-1 or HLA-DR at baseline negatively affected
talquetamab activity. A possible explanation might be that
exhausted or already activated T cells cannot adequately kill MM
cells upon redirection. Furthermore, inferior anti-MM activity of
talquetamab was observed in samples derived from elderly patients,
which was accompanied by impaired T-cell activation and de-
granulation. These findings are in accordance with other studies
showing an age-related decline of the immune system.34 Third, we
observed decreased talquetamab-induced MM cell lysis and
diminished T-cell activation in BM samples with high Treg counts,
compared with samples with low Treg counts. In additional
experiments, we show that Tregs can be redirected to MM cells
in the presence of talquetamab. However, the cytotoxic capacity of
redirected Tregs was significantly lower compared with conven-
tional CD41CD252 T cells, which was reflected by reduced
production of IFN-g, TNF-a, and IL-2. Our data are in line with















































































































































































































































































































































Figure 6. Tregs suppress the proliferation and killing capacity of CD41CD25- effector T cells. (A) Tregs and CD41CD252 effector T cells were isolated from healthy
donor-derived buffy coats by using an immune-magnetic cell isolation kit. Baseline immune cell frequencies and purity of isolated fractions were determined by flow cytometry,
representative density plots are depicted. (B) Effector cells were labeled with violet tracer and incubated with or without Tregs in the presence of anti-CD3/CD28-coated
beads. Proliferation was measured by flow cytometry after 5 days. (C) RPMI-8226 cells were incubated with Tregs and/or effector cells for 48 hours at an E:T ratio of 1:1 and
3:1, with solvent control or talquetamab (4.0 mg/mL). In combination experiments, Tregs and effector T cells were combined in a 1:1 ratio. Lysis of MM cells was determined
using a BLI-based cytotoxicity assay. (D) Cytokine and granzyme B concentrations in cell-culture supernatants were measured using flow cytometry, and concentrations in
talquetamab-treated conditions are depicted as fold change compared with solvent control. Data represent mean 6 SEM of 3 independent experiments, performed in triplicate.
Groups were compared using ANOVA with Tukey’s posttest. *P , .05; **P , .01; ***P , .001; ****P , .0001.
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cells through the granzyme/perforin pathway upon redirection with
an EGFRvIII-specific bispecific antibody.35 In fact, Tregs also
suppress immune responses via direct killing of effector T cells
through release of perforin/granzyme effector molecules.36 More-
over, we show that Tregs impaired the ability of conventional T cells
to kill MM cells. It is currently unknown to what extent Tregs will
affect clinical outcome with bispecific antibodies in MM, but a high
frequency of Tregs was associated with impaired response to the
CD19xCD3 BiTE blinatumomab in patients with acute lymphoblas-
tic leukemia.37 Additional studies are warranted to clarify the role of
other immune suppressor cells, such as regulatory B cells and myeloid-
derived suppressor cells, in modulating the ability of talquetamab to
kill MM cells. Finally, similar to cell adhesion-mediated drug resistance,
direct contact of MM cells with BMSCs contributed to the induction
of talquetamab resistance, at least in part through reducing
GPRC5D expression on MM cells. Additional studies are needed
to fully elucidate how the BMSC-MM cell interaction in the
microenvironment contributes to resistance against talquetamab.
Improved understanding of mechanisms that contribute to innate
resistance to talquetamab may result in the rational design of new
talquetamab-based combinations. Pending validation of our results
in clinical studies, patients with high Treg counts may benefit from
Treg depletion strategies, such as low-dose cyclophosphamide.38-40
In addition, combination strategies with established anti-MM


































































































































































































































































































































































































































Figure 7. Co-incubation with daratumumab (DARA) or pomalidomide (POM) enhances talquetamab-mediated lysis. (A) BM-MNCs obtained from 8 NDMM,
11 daratumumab-naı̈ve RRMM. and 6 daratumumab-refractory RRMM patients were incubated for 48 hours with serial dilutions of talquetamab (0.00128-0.8 mg/mL) with or
without daratumumab 0.1 mg/mL. Surviving MM cells were enumerated using flow cytometry. (B) The effect of talquetamab with or without daratumumab on the frequency of
CD381 T cells, CD381 CD41 T cells, and CD381 CD81 T cells was assessed by flow cytometric analysis. (C) The impact of talquetamab with or without daratumumab on
T-cell lysis, T-cell activation (CD25 positivity), and T-cell degranulation (CD107a positivity) was determined by flow cytometry. (D) For pomalidomide experiments, BM-MNCs
obtained from 5 NDMM, 1 RRMM, and 7 DARA-R MM patients were incubated for 48 hours with serial dilutions of talquetamab (0.00128-4.0 mg/mL) with or without pomali-
domide (2 mM). MM cell lysis was assessed by flow cytometry. (E) T-cell lysis, T-cell activation (CD25 positivity) and T-cell degranulation (CD107a positivity) were measured by
flow cytometry. (F) Granzyme B concentration was measured in the cell-culture supernatants of BM-MNCs, obtained from 5 patients, treated for 48 hours with serial dilutions
of talquetamab (0.00128-0.8 mg/mL) with or without pomalidomide (2 mM). Granzyme B concentrations are depicted as fold change compared with solvent control. (B-C,E-F)
Results of talquetamab monotherapy were compared with combinatorial treatment by nonlinear regression analysis with matched 2-way ANOVA and Sidak’s posttest. (A-F)
Data are depicted as mean 6 SEM of individual experiments, performed in duplicate. *P , .05; **P , .01; ***P , .001; ****P , .0001.
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antibodies. We show that addition of the immunostimulatory drug
pomalidomide or the CD38-targeting antibody daratumumab to
talquetamab enhanced lysis of primary MM cells in an additive
fashion. Coculture with pomalidomide increased talquetamab-
mediated T-cell activation and granzyme B secretion. In additional
cell line experiments, we showed that pomalidomide and talqueta-
mab combination treatment was also associated with a trend
toward a lower Treg frequency compared with talquetamab alone.
This is in accordance to what was observed by Cho et al with the
combination of pomalidomide and the BCMA-targeting bispecific
antibody AMG-701.41 Daratumumab almost completely abrogated
the talquetamab-mediated upregulation of CD38, but this had no
negative impact on T-cell numbers. In fact, reduced CD38
expression on T cells may have beneficial immunomodulatory
effects, because NADase activity of CD38 has been proposed to
contribute to the development of T-cell exhaustion via reducing
nicotinamide adenine dinucleotide levels.42 Indeed, CD38-targeting
antibodies increase nicotinamide adenine dinucleotide levels in
T cells, which leads to an enhanced antitumor T-cell immune
response in mouse models.42 Daratumumab also moderately
reduced the proportion of activated and degranulated T cells,
which may be explained by our findings that besides T cells, also
other cell types (eg, NK cells) are involved in killing MM cells with the
combination of daratumumab and talquetamab.
The restricted GPRC5D expression profile indicates that the
potential for undesired on target/off tumor effects is small. We
hypothesized that GPRC5D-based therapy would have less impact
on GPRC5Dlow normal PCs and thereby may lead to a lower
frequency of hypogammaglobulinemia, which is frequently observed
with CD38-targeted therapies23 and contributes to development of
infections. Although at a low dose of talquetamab, lysis of normal
PCs was modest; a higher dose resulted in substantial elimination
of normal PCs. Ongoing clinical studies will demonstrate whether
the relatively low GPRC5D expression on normal PCs translates
into a lower frequency of hypogammaglobulinemia and infections.
In conclusion, we have confirmed the high expression of GPRC5D
on malignant PCs and have demonstrated that talquetamab,
a bispecific antibody that engages T cells to cells that express
GPRC5D, has substantial activity against MM cell lines and
primary MM cells. We show in ex vivo experiments that tumor-
related factors, as well as differences in the composition of the BM
microenvironment, including the frequency of effector cells (T cells)
and immune suppressor cells (Tregs), contribute to the variability in
response to talquetamab. Our data strengthen the preclinical
rationale for the ongoing clinical trials evaluating talquetamab alone
or in combination with daratumumab or pomalidomide in heavily
pretreated MM patients43 (NCT03399799, NCT04634552,
NCT04108195).
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